Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

Steven P. Treon, Morie Gertz, Meletios Dimopoulos, Athanasios Anagnostopoulos, Joan Blade, Andrew R. Branagan, Ramon Garcia-Sanz, Stephen Johnson, Eva Kimby, Veronique LeBlond, Jean Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin J. Stone

Research output: Contribution to journalReview article

105 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.

Original languageEnglish (US)
Pages (from-to)3442-3446
Number of pages5
JournalBlood
Volume107
Issue number9
DOIs
StatePublished - May 1 2006

Fingerprint

Waldenstrom Macroglobulinemia
Nucleosides
Alkylating Agents
Education
Salvaging
Cyclophosphamide
Chemotherapy
Vincristine
Therapeutics
Prednisone
Infiltration
Doxorubicin
Dexamethasone
Immunoglobulin M
Toxicity
Bone
Cells
Salvage Therapy
Paraproteinemias
Paris

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Treon, S. P., Gertz, M., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A. R., ... Stone, M. J. (2006). Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia. Blood, 107(9), 3442-3446. https://doi.org/10.1182/blood-2005-02-0833

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia. / Treon, Steven P.; Gertz, Morie; Dimopoulos, Meletios; Anagnostopoulos, Athanasios; Blade, Joan; Branagan, Andrew R.; Garcia-Sanz, Ramon; Johnson, Stephen; Kimby, Eva; LeBlond, Veronique; Fermand, Jean Paul; Maloney, David G.; Merlini, Giampaolo; Morel, Pierre; Morra, Enrica; Nichols, Gwen; Ocio, Enrique M.; Owen, Roger; Stone, Marvin J.

In: Blood, Vol. 107, No. 9, 01.05.2006, p. 3442-3446.

Research output: Contribution to journalReview article

Treon, SP, Gertz, M, Dimopoulos, M, Anagnostopoulos, A, Blade, J, Branagan, AR, Garcia-Sanz, R, Johnson, S, Kimby, E, LeBlond, V, Fermand, JP, Maloney, DG, Merlini, G, Morel, P, Morra, E, Nichols, G, Ocio, EM, Owen, R & Stone, MJ 2006, 'Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia', Blood, vol. 107, no. 9, pp. 3442-3446. https://doi.org/10.1182/blood-2005-02-0833
Treon, Steven P. ; Gertz, Morie ; Dimopoulos, Meletios ; Anagnostopoulos, Athanasios ; Blade, Joan ; Branagan, Andrew R. ; Garcia-Sanz, Ramon ; Johnson, Stephen ; Kimby, Eva ; LeBlond, Veronique ; Fermand, Jean Paul ; Maloney, David G. ; Merlini, Giampaolo ; Morel, Pierre ; Morra, Enrica ; Nichols, Gwen ; Ocio, Enrique M. ; Owen, Roger ; Stone, Marvin J. / Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia. In: Blood. 2006 ; Vol. 107, No. 9. pp. 3442-3446.
@article{d2cc41cea1b24bc3995917d4f88e066e,
title = "Update on treatment recommendations from the Third International Workshop on Waldenstr{\"o}m's Macroglobulinemia",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.",
author = "Treon, {Steven P.} and Morie Gertz and Meletios Dimopoulos and Athanasios Anagnostopoulos and Joan Blade and Branagan, {Andrew R.} and Ramon Garcia-Sanz and Stephen Johnson and Eva Kimby and Veronique LeBlond and Fermand, {Jean Paul} and Maloney, {David G.} and Giampaolo Merlini and Pierre Morel and Enrica Morra and Gwen Nichols and Ocio, {Enrique M.} and Roger Owen and Stone, {Marvin J.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1182/blood-2005-02-0833",
language = "English (US)",
volume = "107",
pages = "3442--3446",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

AU - Treon, Steven P.

AU - Gertz, Morie

AU - Dimopoulos, Meletios

AU - Anagnostopoulos, Athanasios

AU - Blade, Joan

AU - Branagan, Andrew R.

AU - Garcia-Sanz, Ramon

AU - Johnson, Stephen

AU - Kimby, Eva

AU - LeBlond, Veronique

AU - Fermand, Jean Paul

AU - Maloney, David G.

AU - Merlini, Giampaolo

AU - Morel, Pierre

AU - Morra, Enrica

AU - Nichols, Gwen

AU - Ocio, Enrique M.

AU - Owen, Roger

AU - Stone, Marvin J.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.

AB - Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.

UR - http://www.scopus.com/inward/record.url?scp=33646433941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646433941&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-02-0833

DO - 10.1182/blood-2005-02-0833

M3 - Review article

C2 - 16410453

AN - SCOPUS:33646433941

VL - 107

SP - 3442

EP - 3446

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -